Revive Therapeutics Expands Bucillamine Patent Portfolio with North American Filings for Chemical Warfare Agent Treatment
Key Insights
Revive Therapeutics (search) filed U.S. and Canadian patent applications for bucillamine's use in treating victims exposed to chemical warfare agents, expanding its medical countermeasures portfolio.
The company received a granted Canadian patent for bucillamine in infectious disease treatment, including influenza (search) and COVID-19 (search), strengthening long-term exclusivity until 2041.
Bucillamine demonstrates superior antioxidant properties compared to NAC and has over 30 years of clinical use in rheumatoid arthritis (search) in Japan and South Korea.
Revive Therapeutics (search) Ltd. announced two significant intellectual property milestones for bucillamine on March 11, 2026, filing U.S. and Canadian national phase patent applications for chemical warfare agent treatment and receiving a granted Canadian patent for infectious disease applications. The developments position the thiol-based drug as a versatile platform asset across multiple therapeutic areas.
Patent Portfolio Expansion
The company filed patent applications under PCT/CA2024/000008 titled "Compositions, Methods and Uses of Bucillamine in the Treatment of a Victim Exposed to a Chemical Warfare Agent" in both the United States (application 19/518,001) and Canada (application 3,304,264). Simultaneously, Revive received Canadian Patent No. 3,172,170 for "Use of Bucillamine in the Treatment of Infectious Diseases," granted on March 10, 2026, with expiration on March 16, 2041.
The North American patent filings expand Revive's position in medical countermeasures, an area encompassing government preparedness, emergency response and stockpiling programs for chemical and biological threats. U.S. government emergency-preparedness programs already maintain stockpiled antidotes, antitoxins and nerve-agent response assets, underscoring the strategic importance of this category.
Clinical Foundation and Mechanism of Action
Bucillamine brings substantial clinical history, including more than 30 years of use in rheumatoid arthritis (search) in Japan and South Korea. According to Revive, the drug demonstrates significantly greater effectiveness than NAC as an antioxidant, with potential to support neuroprotection in nerve-agent exposure models.
The technical white paper "Bucillamine as a Novel Countermeasure for Nerve Agent Exposure" outlines bucillamine's potential relevance in nerve-agent exposure through its ability to donate thiols, replenish glutathione, activate the Nrf2 pathway (search), and potentially help preserve GABA(A) receptor (search) function during oxidative stress and seizure-related injury.
Government Research Collaboration
Revive maintains an active research collaboration with Defence R&D Canada (search) - Suffield Research Centre (DRDC), an agency within Canada's Department of National Defence. DRDC is evaluating compounds, including bucillamine, that may mitigate nerve agent-induced brain injury. Positive outcomes could support further studies aimed at potential regulatory pathways in nerve agents or organophosphate pesticide poisoning.
Following recent discussions with DRDC, the bucillamine research study is expected to conclude with results shortly. Any findings from the study will be released only with express authorization from DRDC.
Strategic Platform Opportunity
Michael Frank, Chief Executive Officer of Revive, stated: "The grant of our Canadian patent for infectious diseases and the advancement of our nerve-agent patent filings in the U.S. and Canada represent a major step forward for Revive and for the long-term value of bucillamine. We believe these milestones validate bucillamine as a versatile platform asset with the potential to address significant unmet needs in infectious diseases, public-health emergencies and government-funded medical countermeasures."
The granted Canadian patent covers methods and uses of bucillamine for treatment or prevention of infectious diseases, including influenza (search) and COVID-19 (search), strengthening Revive's long-term exclusivity around one of its most important pipeline assets.
Broader Applications and Development Experience
Beyond nerve agent exposure and infectious diseases, Revive has identified additional possible applications for bucillamine in organophosphate pesticide poisoning, traumatic brain injury (search), viral infections and long COVID (search), which could expand the commercial relevance of the asset over time.
The company has previously advanced bucillamine through late-stage human clinical development, adding operational and regulatory experience to the program. Combined with its long-standing history of clinical use in Asia, Revive believes bucillamine stands out as a de-risked molecule from a development perspective relative to many early-stage platform assets.
Frank added: "We believe Revive is building a highly strategic bucillamine franchise with meaningful upside. With patent protection now strengthened in infectious diseases, new patent filings advancing in nerve-agent exposure, and ongoing work with DRDC, we are increasingly positioned to pursue value across therapeutic, public-health and national-preparedness markets. Bucillamine is not a one-indication story - it is a platform opportunity."